Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives $26.00 Consensus Target Price from Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) have earned an average recommendation of “Buy” from the seven analysts that are covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $26.00.

Several equities analysts recently commented on the stock. Morgan Stanley reiterated an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Finally, TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock.

Centessa Pharmaceuticals Trading Up 1.6 %

Centessa Pharmaceuticals stock opened at $16.77 on Thursday. Centessa Pharmaceuticals has a 52 week low of $7.75 and a 52 week high of $19.09. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The firm has a market capitalization of $2.21 billion, a PE ratio of -10.96 and a beta of 1.54. The business’s 50-day simple moving average is $16.46 and its 200-day simple moving average is $16.36.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.04, for a total value of $170,400.00. Following the sale, the insider now owns 183,266 shares in the company, valued at approximately $3,122,852.64. The trade was a 5.17 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Saurabh Saha sold 55,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $17.44, for a total value of $959,200.00. Following the transaction, the chief executive officer now directly owns 520,661 shares of the company’s stock, valued at approximately $9,080,327.84. This trade represents a 9.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 260,168 shares of company stock valued at $4,357,818. 11.59% of the stock is currently owned by corporate insiders.

Institutional Trading of Centessa Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in Centessa Pharmaceuticals in the 3rd quarter valued at $2,834,000. Wellington Management Group LLP acquired a new stake in shares of Centessa Pharmaceuticals in the third quarter valued at about $1,609,000. State Street Corp bought a new stake in Centessa Pharmaceuticals during the third quarter worth about $777,000. GSA Capital Partners LLP boosted its position in Centessa Pharmaceuticals by 66.1% during the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock valued at $1,498,000 after purchasing an additional 37,275 shares during the last quarter. Finally, Ally Bridge Group NY LLC acquired a new position in shares of Centessa Pharmaceuticals during the 3rd quarter worth approximately $4,951,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.